Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...

Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer Findings highlight inflammation as a driver of lung tumor ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Severe COVID-19 raises lung cancer risk by 24%, study of 76 million Americans finds In A Nutshell People hospitalized with severe COVID-19 had roughly a 24 percent higher risk of developing lung ...

It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...